Ligand binding to the (1→3)-β-D-glucan receptor stimulates NFκB activation, but not apoptosis in U937 cells

Biochemical and Biophysical Research Communications

Volumn 249, Issue 2, 1998, Pages 499-504

  Battle, James ^a   Ha, Tuanzhu ^a   Li, Chaunfu ^a   Beffa, Vittorio Della ^a   Rice, Peter ^a   Kalbfleisch, John ^a   Browder, William ^a   Williams, David ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; RECEPTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; MACROPHAGE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0032547235     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1998.9175     Document Type: Article

References (28)

1. Ayala A., Urbanich M. A., Herdon C. D., Chaudry I. H. Is sepsis-induced apoptosis associated with macrophage dysfunction. J. Trauma Injury Infect. Crit. Care. 40:1996;568-574.
2. Ayala A., Karr S. M., Evans T. A., Chaudry I. H. Factors responsible for peritoneal granulocyte apoptosis during sepsis. J Surg Res. 69:1997;67-75.
3. Ayala A. Lymphoid apoptosis during sepsis: Now that we've found it, what do we do with it. Crit Care Med. 25:1997;1261-1262.
4. Baldwin A. S. Jr. The NF-kappa B and I-kappa B proteins: New discoveries and insights. Ann Rev Immunol. 14:1996;649-683.
5. Böhrer H., Qiu F., Zimmermann T., Zhang Y., Jilmer T., Männel D., Böttiger B. W., Stern D. M., Waldherr R., Saeger H. D., Ziegler R., Bierhaus A., Martin E., Nawroth P. P. Role of NFκB in the Mortality of Sepsis. J Clin Invest. 100:1997;972-985.
6. Iimuro Y., Nishiura T., Hellerbrand C., Behrns K. E., Schoonhoven R., Grisham J. W., Brenner D. A. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest. 101:1998;802-811.
7. Wang C. Y., Mayo M. W., Baldwin A. S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science. 274:1996;784-787.
8. Ruckdeschel K., Harb S., Roggenkamp A., Hornef M., Zumbihl R., Kohler S., Heesemann J., Rouot B. Yersinia enterocolitica impairs activation of transcription factor NF-kappaB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor alpha production. J Exp Med. 187:1998;1069-1079.
9. Williams D. L., McNamee R. B., Jones E. L., Pretus H. A., Ensley H. E., Browder I. W., Di Luzio N. R. A method for the solubilization of a (1-3)-β-D-glucan isolated fromSaccharomyces cerevisiae. Carbohyd Res. 219:1991;203-213.
10. Ensley H. E., Tobias B., Pretus H. A., McNamee R. B., Jones E. L., Browder I. W., Williams D. L. NMR spectral analysis of a water-insoluble (1-3)-β-D-glucan isolated fromSaccharomyces cerevisiae. Carbohydr Res. 258:1994;307-311.
11. Williams D. L., Mueller A., Browder W. Glucan-based macrophage stimulators: a review of their anti-infective potential. Clin Immunother. 5:1996;392-399.
12. Williams D. L., Mueller A., Browder W. Preclinical and clinical evaluation of carbohydrate immunopharmaceuticals in the prevention of sepsis and septic sequelae. J Endotox Res. 2:1995;203-208.
13. Williams D. L., Sherwood E. R., Browder I. W., McNamee R. B., Jones E. L., Rakinic J., Di Luzio N. R. Effect of glucan on neutrophil dynamics and immune function inEscherichia coli. J Surg Res. 44:1988;54-61.
14. Browder W., Williams D., Pretus H., Olivero G., Enrichens F., Mao P., Franchello A. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg. 211:1990;605-613.
15. de Felippe J., Rocha e Silva M. D., Maciel F. M. B., Soares A. D. M., Mendes N. F. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gyn Obstet. 177:1993;383-388.
16. Babineau T. J., Marcello P., Swails W., Kenler A., Bistrian B., Forse R. A. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 220:1994;601-609.
17. Babineau T. J., Hackford A., Kenler A., Bistrian B., Forse R. A., Fairchild P. G., Heard S., Keroack M., Causha P., Benotti P. A Phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PPG-glucan) in high-risk surgical patients. Arch.Surg. 129:1994;1204-1210.
18. Adams D. S., Pero S. C., Petro J. B., Nathans R., Mackin W. M., Wakshull E. PGG-Glucan activates NF-κB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. J Leuk Biol. 62:1997;865-873.
19. Mueller A., Rice P. J., Ensley H. E., Coogan P. S., Kalbfleisch J. H., Kelley J. L., Love E. J., Portera C. A., Ha T., Browder I. W., Williams D. L. Receptor binding and internalization of water-soluble (1→3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines. J Immunol. 156:1996;3418-3425.
20. Um H. D., Orenstein J. M., Wahl S. M. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol. 156:1996;3469-3477.
21. Põrn-Ares M. I., Chow S. C., Slotte J. P., Orrenius S. Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in u937 cells by the xanthogenate compound D609. Exp Cell Res. 235:1997;48-54.
22. Pretus H. A., Ensley H. E., McNamee R. B., Jones E. L., Browder I. W., Williams D. L. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J Pharmacol Exp Ther. 257:1991;500-508.
23. Williams D. L., Browder I. W., DiLuzio N. R. Immunotherapeutic modification ofEscherichia coli. Surgery. 93:1982;448-454.
24. Thornton B. P., Vetvicka V., Pitman M., Goldman R. C., Ross G. D. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol. 156:1996;1235-1246.
25. Rasmussen L. T., Fandrem J., Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta-1,3-D-polyglucose derivatives. II. Interleukin 1, tumour necrosis factor, prostaglandin E2, and leukotriene B4. Scand J Immunol. 32:1990;321-331.
26. Rasmussen L. T., Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta-1,3-D-polyglucose derivatives. I. Cells. Scand J Immunol. 32:1990;321-331.
27. Onderdonk A. B., Cisneros R. L., Hinkson P., Ostroff G. Anti-Infective Effect of Poly-β1-6-Glucotriosyl-β1-3-Glucopyranose GlucanIn Vivo. Infect Immun. 60:1992;1642-1647.
28. Müller A., Pretus H. A., Williams D. L., McNamee R. B., Jones E. L., Browder I. W. Comparison of the carbohydrate Biological Response Modifiers Krestin, Lentinan, Schizophyllan and Glucan Phosphate by aqueous gel permeation chromatography with in-line multi-angle laser light scattering photometry and differential viscometry detectors. J. Chromatogr. 666:1995;283-290.